Anna S. F. Lok

Antiviral options for the treatment of chronic hepatitis B (2006)

Osborn, Melissa K., Lok, Anna S. F.

Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinoma. Effective treatment can delay or prevent these outcomes. The decision to treat is based on the...

Antiviral options for the treatment of chronic hepatitis B (2006)

Osborn, Melissa K., Lok, Anna S. F.

Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinoma. Effective treatment can delay or prevent these outcomes. The decision to treat is based on the...

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial

Everson, Gregory T., Hoefs, John C., Seeff, Leonard B., Bonkovsky, Herbert L., Naishadham, Deepa, Shiffman, Mitchell L., ...

In patients with chronic hepatitis C, advanced fibrosis and cirrhosis are associated with lower rates of sustained virologic response (SVR) to interferon (IFN)-based therapy. In this study, we...

Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation

Terrault, Norah A., Shiffman, Mitchell L., Lok, Anna S.F., Saab, Sammy, Tong, Lan, Brown, Robert S., ...

In this retrospective study of hepatitis C virus (HCV)–infected transplant recipients in the 9-center Adult to Adult Living Donor Liver Transplantation Cohort Study, graft and patient survival and...

Chronic hepatitis B Potential conflict of interest: Dr. McMahon's spouse owns stock in GlaxoSmithKline. Dr. Lok is a consultant for, received grants, and is on the Scientific Advisory Board of, Bristol-Myers Squibb, GlaxoSmithKline, Idenix, Roche, Gilead, and Innogenetics. She is also on the Scientific Advisory Board of Pharmasset. Dr. Lok received grants from Schering-Plough. Please refer to www.aasld.org for disclosures by Practice Guidelines Committee members.

Lok, Anna S. F., McMahon, Brian J.

No abstract.

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma

Wong, Stephen N., Reddy, K. Rajender, Keeffe, Emmet B., Han, Steven-Huy, Gaglio, Paul J., Perrillo, Robert P., ...

Patients with hepatocellular carcinoma (HCC) receive a higher MELD score and may undergo liver transplantation (OLT) earlier compared to patients with cirrhosis, potentially decreasing waiting list...

Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B See Article on Page 349

Tan, Jessica, Lok, Anna S.F.

No abstract.

Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

Wong, Stephen N., Chu, Chi-Jen, Wai, Chun-Tao, Howell, Terese, Moore, Charles, Fontana, Robert J., ...

Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver...

Management of hepatitis B: Summary of a clinical research workshop Potential conflict of interest: Dr. Lok is a consultant and received grants from GlaxoSmithKline, Bristol-Myers Squibb, Idenix, Gilead, Roche, and Innogenetics.

Hoofnagle, Jay H., Doo, Edward, Liang, T. Jake, Fleischer, Russell, Lok, Anna S.F.

Chronic hepatitis B is caused by persistent infection with the hepatitis B virus (HBV), a unique DNA virus that replicates through an RNA intermediate produced from a stable covalently closed...

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

Fontana, Robert J., Bieliauskas, Linas A., Lindsay, Karen L., Back-Madruga, Carla, Wright, Elizabeth C., Snow, Kristin K., ...

Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can cause or exacerbate depression but its effects on cognitive function are largely unknown. The aim of this...

Corrections to AASLD guidelines on chronic hepatitis B Potential conflict of interest: Nothing to report.

Lok, Anna S. F., McMahon, Brian J.

No abstract.

Reply: Potential conflict of interest: Nothing to report.

Lok, Anna S. F., McMahon, Brian J., Lok, Anna S. F., McMahon, Brian J.

No abstract.

Reply: Potential conflict of interest: Nothing to report.

Lok, Anna S. F., McMahon, Brian J., Lok, Anna S. F., Mcmahon, Brian J.

No abstract.

Reply: Potential conflict of interest: Nothing to report.

Lok, Anna S.F., McMahon, Brian J., Lok, Anna S.F., McMahon, Brian J.

No abstract.

Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation See Editorial on Page 1084

Hussain, Munira, Soldevila-Pico, Consuelo, Emre, Sukru, Luketic, Velimir, Lok, Anna S.F.

Previous studies reported that hepatitis B virus (HBV) deoxyribonucleic acid (DNA) can be detected in livers of patients who received transplants for hepatitis B despite the absence of serological...

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial

Seeff, Leonard B., Curto, Teresa M., Szabo, Gyongyi, Everson, Gregory T., Bonkovsky, Herbert L., Dienstag, Jules L., ...

Herbal products, used for centuries in Far Eastern countries, are gaining popularity in western countries. Surveys indicate that persons with chronic hepatitis C (CHC) often use herbals, especially...